Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48-week extension safety study of TOBI Podhaler in cystic fibrosis
2012-003532-23Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tobramycin in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection, sponsored by Novartis. Primary endpoint: Incidence of treatment-emergent adverse events. Started Oct 2012; status: completed.
02
Drugs
tobramycin
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on 2012-003532-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003532-23.